ATE404216T1 - Verstärker der hm1.24 antigen-expression - Google Patents

Verstärker der hm1.24 antigen-expression

Info

Publication number
ATE404216T1
ATE404216T1 AT00953561T AT00953561T ATE404216T1 AT E404216 T1 ATE404216 T1 AT E404216T1 AT 00953561 T AT00953561 T AT 00953561T AT 00953561 T AT00953561 T AT 00953561T AT E404216 T1 ATE404216 T1 AT E404216T1
Authority
AT
Austria
Prior art keywords
interferon
amplifier
antigen
antigen expression
expression
Prior art date
Application number
AT00953561T
Other languages
German (de)
English (en)
Inventor
Masaaki Kosaka
Shuji Ozaki
Yuji Wakahara
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE404216T1 publication Critical patent/ATE404216T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00953561T 1999-08-23 2000-08-22 Verstärker der hm1.24 antigen-expression ATE404216T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23600799 1999-08-23
JP2000038689 2000-02-16

Publications (1)

Publication Number Publication Date
ATE404216T1 true ATE404216T1 (de) 2008-08-15

Family

ID=26532447

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00953561T ATE404216T1 (de) 1999-08-23 2000-08-22 Verstärker der hm1.24 antigen-expression

Country Status (12)

Country Link
US (1) US8287863B2 (enExample)
EP (1) EP1213028B1 (enExample)
JP (1) JP4671570B2 (enExample)
KR (1) KR20020025990A (enExample)
CN (1) CN1370076A (enExample)
AT (1) ATE404216T1 (enExample)
AU (1) AU784460B2 (enExample)
CA (1) CA2382587A1 (enExample)
DE (1) DE60039893D1 (enExample)
ES (1) ES2307526T3 (enExample)
TW (2) TWI248365B (enExample)
WO (1) WO2001013940A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI248365B (en) 1999-08-23 2006-02-01 Chugai Pharmaceutical Co Ltd HM1.24 antigen expression potentiators
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
EP2208784B1 (en) * 2001-06-22 2013-01-02 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican 3 antibody
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
CA2660795C (en) * 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
WO2010045570A1 (en) * 2008-10-16 2010-04-22 Childerns Hospital Los Angeles Methods and compositions for inhibiting propagation of viruses using recombinant tetherin constructs
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) * 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
MX9305855A (es) 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
TW442493B (en) 1993-10-15 2001-06-23 Toshio Hirano A membrane protein polypeptide having pre-B cell growth-supporting ability and a gene thereof
JP3412930B2 (ja) 1993-10-15 2003-06-03 俊夫 平野 プレｂ細胞増殖支持能を有する膜タンパクポリペプチド及びその遺伝子
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
JP3554355B2 (ja) 1994-03-03 2004-08-18 中外製薬株式会社 Ｉｌ−６オートクライン増殖性ヒト骨髄腫細胞株
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
ATE306930T1 (de) 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
JP3651697B2 (ja) * 1995-03-24 2005-05-25 株式会社アミノアップ化学 新規多糖体物質
WO1996030394A1 (en) 1995-03-31 1996-10-03 Jakob Bohr Method for protein folding
EP0823257B1 (en) * 1995-04-02 2002-08-07 Chugai Seiyaku Kabushiki Kaisha Medicinal composition for curing thrombocytopenia
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
CA2280875C (en) * 1997-02-12 2005-07-05 Chugai Seiyaku Kabushiki Kaisha Remedies for lymphocytic tumors
EP1023906A4 (en) * 1997-10-14 2005-03-02 Chugai Pharmaceutical Co Ltd AMPLIFIER FOR ANTIBODY AGAINST LYMPHOIDEN TUMOR
TWI248365B (en) 1999-08-23 2006-02-01 Chugai Pharmaceutical Co Ltd HM1.24 antigen expression potentiators
CA2412901A1 (en) 2000-06-22 2001-12-27 Idec Pharmaceutical Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
JP3986439B2 (ja) * 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤

Also Published As

Publication number Publication date
CN1370076A (zh) 2002-09-18
US20060193828A1 (en) 2006-08-31
KR20020025990A (ko) 2002-04-04
WO2001013940A1 (en) 2001-03-01
EP1213028A1 (en) 2002-06-12
TW200528127A (en) 2005-09-01
CA2382587A1 (en) 2001-03-01
TWI290832B (en) 2007-12-11
ES2307526T3 (es) 2008-12-01
EP1213028B1 (en) 2008-08-13
AU784460B2 (en) 2006-04-06
TWI248365B (en) 2006-02-01
DE60039893D1 (enExample) 2008-09-25
US8287863B2 (en) 2012-10-16
AU6598900A (en) 2001-03-19
JP4671570B2 (ja) 2011-04-20
EP1213028A4 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
DK0975635T3 (da) Svampedræbende trifluormethylalkylamino-triazolpyrimidiner
DK0652229T3 (da) Oligopeptider med fungicid virkning
DE69432035D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
ATE170868T1 (de) Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
DK0975634T3 (da) Fungicide trifluorphenyl-triazolpyrimidiner
DK2208784T3 (da) Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
ATE249219T1 (de) Antivirale verbindungen
TR199801582T2 (xx) Bakteri �ld�r�c� ve mantar �ld�r�c� peptit.
DK0601154T3 (da) BPC-peptider, deres fremstilling og anvendelse
ATE404216T1 (de) Verstärker der hm1.24 antigen-expression
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
MX9305196A (es) Novedosos 2-sacarinilmetil aril carboxilatos utiles como inhibidores de enzima proteolitica y composiciones y metodos de su uso.
BR9612196A (pt) Tiazolinas substituidas
ATE365734T1 (de) Herbizide furanyl- und thienyloxyazine
ATE247649T1 (de) Disubstituierte biphenyloxazoline
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
IT1216103B (it) Peptidi ad attivita' farmaceutica.
EA200200373A1 (ru) Фунгициды
DE3772926D1 (de) Verfahren zur stabilisierung von procaterol.
IT8622051A1 (it) Composizioni farmaceutiche ad attivita' cicatrizzante
DK1144407T3 (da) Cycliske guanidinderivater samt deres anvendelse som pesticider

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties